Susquehanna Fundamental Investments LLC Has $649,000 Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Susquehanna Fundamental Investments LLC raised its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) by 825.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 132,998 shares of the company’s stock after buying an additional 118,628 shares during the quarter. Susquehanna Fundamental Investments LLC owned 0.16% of Verve Therapeutics worth $649,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in VERV. Capstone Investment Advisors LLC acquired a new position in Verve Therapeutics in the fourth quarter valued at approximately $142,000. NEOS Investment Management LLC acquired a new position in Verve Therapeutics in the fourth quarter valued at approximately $192,000. Rafferty Asset Management LLC lifted its stake in Verve Therapeutics by 10.0% in the fourth quarter. Rafferty Asset Management LLC now owns 351,904 shares of the company’s stock valued at $4,906,000 after buying an additional 32,104 shares during the period. Bellevue Group AG acquired a new position in Verve Therapeutics in the fourth quarter valued at approximately $544,000. Finally, Sierra Summit Advisors LLC acquired a new position in Verve Therapeutics in the fourth quarter valued at approximately $177,000. 97.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on VERV. Royal Bank of Canada dropped their price target on Verve Therapeutics from $25.00 to $20.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Verve Therapeutics in a report on Monday, August 12th. Finally, Canaccord Genuity Group decreased their price objective on Verve Therapeutics from $30.00 to $29.00 and set a “buy” rating for the company in a report on Monday, August 12th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Verve Therapeutics has an average rating of “Buy” and a consensus target price of $26.00.

Verve Therapeutics Trading Up 0.2 %

Shares of Verve Therapeutics stock opened at $4.80 on Thursday. The stock has a fifty day simple moving average of $5.57 and a 200 day simple moving average of $6.51. Verve Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $20.12. The company has a market capitalization of $406.18 million, a P/E ratio of -1.67 and a beta of 1.83.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.09. Verve Therapeutics had a negative return on equity of 35.20% and a negative net margin of 933.08%. The business had revenue of $6.70 million during the quarter, compared to the consensus estimate of $2.40 million. During the same quarter in the prior year, the company posted ($0.87) earnings per share. Verve Therapeutics’s revenue was up 219.0% compared to the same quarter last year. On average, analysts predict that Verve Therapeutics, Inc. will post -2.65 EPS for the current year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.